RHY.ASX: Response to ASX Price Query

Response to ASX Price Query

Stock	RHYTHM Biosciences Ltd (RHY.ASX)
Release Time	6 Aug 2025, 2:36 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Rhythm Biosciences responds to ASX price query

Key Points

No information known that has not been announced to the market
Confirming compliance with ASX Listing Rules
Providing background on company and key products

Full Summary

Rhythm Biosciences Limited (ASX: RHY) has provided a response to an ASX price query regarding the recent trading in its securities. The company confirmed that it is not aware of any information concerning it that has not been announced to the market and which could explain the recent trading. Rhythm Biosciences also confirmed that it is complying with the ASX Listing Rules, particularly Listing Rule 3.1. The announcement provided background on the company, including information about its key products ColoSTAT and geneType. ColoSTAT is Rhythm Biosciences' simple blood test for the detection of colorectal cancer, while geneType is a genetic risk assessment testing platform covering multiple diseases. The company stated that it is committed to working with global partners to achieve commercialization and distribution of these solutions, with the aim of improving patient outcomes through early detection and reducing the global burden of cancer.